In a significant breakthrough for Parkinson’s disease treatment, Annovis Bio’s stock surged following the release of promising new data regarding their drug, Buntanetap. The study revealed that Buntanetap effectively halts cognitive decline in patients with Parkinson’s disease, sparking investor interest and optimism about future therapeutic possibilities. The intriguing data highlights Buntanetap’s potential as a crucial component in slowing down the progression of cognitive symptoms, a major challenge in Parkinson’s treatment. With millions affected by Parkinson’s worldwide, this development offers hope for improved quality of life and disease management. Annovis Bio’s strategic focus on neurological health continues to pay off as it pushes boundaries in Parkinson’s research. The company is poised to capture a substantial share of the neuroprotective drug market, reflecting its commitment to innovation and patient care. This advancement in Parkinson’s treatment may lead to further studies and potential regulatory approvals, reinforcing Annovis Bio’s position as a leader in neurological therapies.
BenzingaNew data shows smarter solutions to change-of-mind returns as retailers crack down
August 3, 2026
In a bid to address the rising costs associated with change-of-mind returns, many retailers are implementing stricter policies. However, recent data suggests that a more